Symptoms (with prolonged reception of doses exceeding the recommended): impaired renal function. These symptoms are completely reversible when canceling Bismuthate tripotassium dicitratea®.
Treatment: gastric lavage, the purpose of activated carbon and salt laxatives. Further treatment should be symptomatic. In case of impaired renal function, accompanied by a high level of vismut in the blood plasma, the use of complex converters is dimercaptoantar and dimercaptopropanasulfonic acid. In the event of a pronounced violation of the function of the kidneys, hemodialysis is shown.
individual intolerance of the drug ;
pronounced violation of the function of the kidneys ;
pregnancy;
period of breastfeeding.
Within half an hour before and after taking Bismuthate tripotassium dicitratea® it is not recommended to use other drugs inside, as well as eating and liquid, in particular antacids, milk, fruits and fruit juices. This is due to the fact that when taken orally, they can affect the effectiveness of Bismuthate tripotassium dicitratea®.
From the digestive system : the appearance of nausea, vomiting, more frequent stool, constipation is possible. These phenomena are not hazardous to health and are temporary.
Allergic reactions : skin rash, itching skin.
For long-term use in high doses - encephalopathy associated with the accumulation of vismut in the central nervous system.
Antificial agent with bactericidal activity in relation Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble vismuta oxychloride and citrate are precipitated, chelate compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosion. Increasing the synthesis of PGE, the formation of mucus and the secretion of hydrocarbonate, stimulates the activity of cytoprotectory mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsiin, hydrochloric acid, enzymes and bile acid salts. It leads to the accumulation of the epidermal growth factor in the defect zone. Reduces the activity of pepsin and pepsinogen.
The vismut subcitrate is practically not absorbed from the LCD. It is derived mainly with feces. A small amount of vismut, received in plasma, is excreted by the kidneys.
